Interventional radiology approaches for intra-hepatic cholangiocarcinoma by Mosconi, Cristina et al.
© Chinese Clinical Oncology. All rights reserved.   Chin Clin Oncol 2019 | http://dx.doi.org/10.21037/cco.2019.12.15
Page 1 of 8
Introduction
The use of loco-regional therapies for the management 
of patients with biliary tract cancer has its rational in 
addressing tumor growth and its local complications. This 
aims to reduce the risk of tumor-related liver failure, the 
most common cause of death among patients with intra-
hepatic cholangiocarcinoma (ICC) (1,2). The use of 
interventional radiology procedures on the management 
of patients with biliary tract cancers can be broadly divided 
in two major goals: loco-regional oncological treatments 
and non-oncological palliative and/or complementary 
procedures for definitive therapy. For the former, 
interventional radiologists apply different loco-regional 
methods that aims to provide effective local oncological 
control, therefore preventing tumor progression and its 
associated complications. Such oncological therapies are 
mainly applied for patients with ICC, with little evidence 
on the literature on the use of interventional radiology 
procedures for the oncological treatment of extra-
hepatic cholangiocarcinoma; for the latter, interventional 
radiology procedures are performed to address tumor-
related complications such as bleeding (i.e., transarterial 
embolization) biliary obstruction (i.e., percutaneous biliary 
drainage) or as a complementary method to definitive 
therapy (i.e., pre-operative portal vein embolization). Such 
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methods have been successfully applied for the management 
of both intra- and extra-hepatic cholangiocarcinoma 
patients.
In this review, we aim to provide a literature review on 
the use of different interventional radiology procedures for 
the loco-regional oncological treatment of patients with 
ICC. Palliative and complementary methods to definitive 
therapy are not in the scope of the present review and were 
not included in this review. Finally, future directions on the 
role of such loco-regional oncological treatments offered by 
interventional radiology are discussed.
Liver ablation
The use of image-guided thermal ablation on the treatment 
of ICC was initially reported two decades ago in a mixed 
series of primary liver cancer treatments. Specific application 
of thermal ablation for the ICC was reported for the first 
time in 2002 by Slakey (3). Although ICC is the second 
most common liver tumor after hepatocellular carcinoma, 
due to its relatively low incidence and advanced tumor 
burden once diagnosed (4), data on the efficacy and safety 
of thermal ablation in this specific setting are limited if 
compared to other primary and secondary tumors affecting 
the liver. Indeed, contrarily to its curative role on patients 
with hepatocellular carcinoma classified as very early 
and early stages according to the Barcelona Clinic Liver 
Cancer (BCLC) Staging and treatment classification (5), 
thermal ablation is still considered a palliative treatment in 
the ICC guidelines (6).
The most commonly util ized imaging-guidance 
modalities to perform liver ablation consists of ultrasound 
in  Europe  and Eastern  countr ies  and computed 
tomography (CT) in the United States. During image-
guided ablation, thermal energy is delivered to the tumor 
tissue through needle electrodes (in case of radiofrequency 
ablation, RFA) or antennas [in case of microwave ablation 
(MWA)]. In both cases the treatment goal is to reach 
an intra-tumoral temperature between 60 and 100 ℃, 
to obtain coagulative necrosis. Although RFA has been 
the most studied ablation modality for ICC, recent 
evidences support MWA as a valid alternative (7). Indeed, 
MWA offers many theoretical advantages, including less 
dependence on electrical conductivity of tissue, a reduced 
time of ablation, higher intra-tumoral temperature, and 
larger ablation zone (8,9). 
Ablation can be offered for patients with ICC who are 
not eligible to surgery with small, localized tumors without 
evidence of extrahepatic spread (3,10-12). Furthermore, 
due to high recurrence rates of ICC following surgery, 
ablation has a relevant role in post-resection recurrence 
(10,13,14). Zhang et al. reported the role of repeated 
resection (n=32) and thermal ablation (n=77) in patients 
with ICC presenting with post-resection recurrence. 
Authors found no differences (P=0.99) in overall survival 
(OS) and disease-free survival rates between repeated 
resection and thermal ablation. Nevertheless, in a subset of 
patients with recurrence tumors >3 cm, repeated resection 
provided improved OS when compared to thermal ablation. 
Expectedly, major complications were more common in the 
repeated resection group (P<0.001). Based on their findings, 
authors concluded that thermal ablation should be preferred 
in patients with ICC recurrence measuring ≤3 cm (13).
Lesion size is a relevant factor for achieving complete 
ablation and reduced rates of local recurrence, also known 
on the ablation literature as local tumor progression (LTP). 
It has been suggested a maximum diameter of 3 cm as 
a threshold for ablation eligibility for both primary and 
recurrent ICC (6), which is consistent with the existing liver 
ablation literature for other tumors types. Furthermore, the 
3 cm cut-off has been identified in the surgical literature 
to distinguish anatomo-pathological findings, such as a 
lower incidence of well-differentiated cholangiocarcinoma 
without microvascular invasion from poorly differentiated 
tumors with microvascular invasion (15). 
Minimal ablation margins is a relevant factor associated 
with ablation outcomes of patients with HCC and colorectal 
liver metastasis. Presently, the literature is still lacking of 
specific and pertinent information regarding the impact 
of minimal ablation margins on ICC. However, data from 
surgical series suggests a relevant role for resection margins 
in order to reduce the local recurrence rates, suggesting a 
desirable 10 mm threshold (16). Finally, other factors such 
as nodes positivity (17), superficially located tumors (18) 
or presence of extrahepatic disease (15) have been reported 
to affect outcomes following ablation. Nevertheless, such 
elements still require more robust confirmation in larger 
patient cohorts. 
A systematic review and meta-analysis of RFA in the 
treatment of unresectable ICC was performed by Han 
et al. (11). This included seven observational studies with 
a total of 84 patients. They found an LTP pooled rates 
of 21%; the lowest LTP rates was reported by Haidu 
et al. (8%) whereas Carrafiello et al. reported the highest 
LTP rates of 50%. Pooled 1-, 3-, and 5-year survival rates 
were 82, 47% and 24%. On the whole, these findings are 
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encouraging, since similar rates were found in metanalysis 
of thermal ablation of other tumor types, such as 
colorectal liver metastases. MWA ablation is a more recent 
technology and few reports are present in the literature. 
However, in the largest published series (107 patients, 171 
treated lesions), Zhang et al. (19) found a median PFS after 
MWA of 8.9 months. The median OS was 28 months; OS 
rates after 1, 3 and 5 years were 93.5%, 39.6% and 7.9%, 
respectively (19). 
Of the published studies, major complications (i.e., any 
event that required additional treatment, including an 
increased level of care, hospital stay beyond observation 
and permanent damage) were reported at least in 4 studies 
with one case of death after liver abscess and subsequent 
sepsis. However, when compared to surgery, complications 
rates of thermal ablation treatments were far below (13). 
Minor adverse events, such as post ablation syndrome and 
abdominal pain, are always reported in all series, but are 
generally resolved spontaneously or with conservative care.
Transarterial chemoembolization (TACE)
Conventional TACE (cTACE) is the most utilized intra-
arterial therapy for patients with ICC. On this procedure, 
an emulsion of chemotherapeutics and an oil-based 
contrast agent (Ethiodol or Lipiodol) followed by an 
embolizing agent is injected into the tumor-supplying 
branch of the hepatic artery. Doxorubicin, cisplatin and 
mitomycin-C and, to a lesser extent, gemcitabine is the 
most commonly used drug combination in the Europe 
and United States (20,21). Inclusion and exclusion criteria 
for cTACE are not different from those for patients with 
hepatocellular carcinoma. In particular, patients should 
have a good hepatic function (Child-Pugh Class A or B) 
and appropriate performance status [Eastern Cooperative 
Oncology Group (ECOG) 0–2]. In cases where tumor-
related biliary occlusion is seen or in patients with prior 
history of bilioenteric manipulation, there might be a 
high-risk to develop postprocedural biliary sepsis and 
liver abscess formation due to chronic biliary colonization 
with intestinal bacterial flora (22). In such circumstances, 
aggressive prophylactic antibiotic regimen might be used 
to prevent infectious complications (23). 
Compared with symptomatic management, it has been 
demonstrated that cTACE is able to improve survival versus 
best supportive care. Also, Scheuermann et al. demonstrated 
similar survival between patients with unresectable ICC 
undergoing cTACE or TACE with drug-eluting beads 
(DEB-TACE) (11 months) and patients undergoing surgery 
with positive resection margins (11 months) or lymph node 
positive disease (9 months) (24). Published series of patients 
with unresectable ICC treated with cTACE reported 
survival from the diagnosis ranging from 12 to 25.2 months 
and survival from the procedure ranging from 9.1 to 16.3 
months (25). However, these studies are characterized by 
great variability in regard to several variables such as tumor 
burden, chemotherapeutic agent administered, and number 
of cTACE sessions. Kiefer et al. (20), in a multicentre study 
with 62 patients who received cTACE with mitomycin 
C, doxorubicin, and cisplatin, showed a median time to 
progression of 8 months, a median OS of 15 months 
from the first cTACE and 20 months from the diagnosis: 
patients treated with systemic chemotherapy and cTACE, 
had a median OS of 28 months (20). Sixty six percent of 
the 45 patients with at least one follow-up showed disease 
stability while 10% showed partial response. Conversely, 
Kuhlmann et al. demonstrated significantly lower results, 
reporting an OS of 5.7 months and a progression-free 
survival (PFS) of only 1.8 months with single-agent 
cTACE (26). Recently, Ray et al. (27) performed a meta-
analysis regarding the efficacy of chemotherapy-based 
transarterial therapies, demonstrating a cumulative median 
OS from date of diagnosis of 15.7 months, and from the 
first TACE treatment of 13.4 months. However, this study 
had some limitations, in particular the non-uniformity of 
data about type of chemotherapies and the use and type 
of the embolic agent; despite the above limitations, in the 
absence of randomized studies, its results demonstrated 
the efficacy and safety of TACE in the ICC treatment, 
being the point of reference in this setting. Generally, 
cTACE is well tolerated with minimal adverse events. The 
more frequently minor side effects are related to post-
embolization syndrome, represented by transient nausea, 
abdominal pain, fever and increase in liver enzymes (limited 
to 3–4 days without the evidence of sepsis) (28), which can 
be usually successfully managed with medical therapy.
Drug-eluting beads transarterial chemoembolization 
(DEB-TACE) combines the local release of chemotherapeutic 
agent(s) from beads and arterial embolization with a decrease 
of blood flow due to the beads, with lower systemic exposure 
to the chemotherapeutic agent when compared conventional 
TACE (29). The studies published with inoperable ICC 
patients treated with DEB-TACE reported survival from 
the procedure ranged from 8.6 to 30 months (25). However, 
the same considerations regarding the non-uniformity of the 
cTACE data may be acknowledged. 
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Transarterial radioembolization (TARE)
The term TARE defines the use of intra-arterially injected 
radioactive microspheres. The purpose of TARE is to 
selectively release a high radiation dose specifically to 
liver tumors and to limit radiation to the normal liver 
parenchyma to within tolerable levels (30). Following the 
administration in the hepatic artery, the microspheres 
are carried by the arterial blood flow toward the most 
distal arterioles inside hepatic tumors. In addition, the 
neovascularization of the plexus surrounding the tumor 
causes an increase density in ICC as compared to the 
liver parenchyma (31), thus allowing an entrapment of 
the microspheres in the tumors. For TARE selection, 
all patients should be evaluated by a multidisciplinary 
group, analyzing clinical history, physical examination, 
and of liver function. In addition, recent and high quality 
radiologic images [CT or magnetic resonance imaging 
(MRI)] are needed, showing unequivocal and measurable 
evidence of ICC which cannot be surgically resected or 
ablated with curative intent (32). The best candidates for 
TARE are patients with unresectable liver-only or liver-
dominant tumors (31). The inclusion criteria are: Eastern 
Cooperation Oncology Group (ECOG) performance status 
of 0, 1 or 2; adequate laboratory tests, in particular absolute 
neutrophil count >1.5 3×109/L, a platelet count >50 3×109/L, 
renal function with creatinine level <2.0 mg/dL, and 
adequate liver function with bilirubin <2.0 mg/dL; and 5) 
the possibility to perform angiographic study of the liver 
vessels. Exclusion criteria include presence of shunting with 
gastrointestinal arteries that cannot be embolized; lungs 
estimated radiation doses greater than 30 Gy, and presence 
of extra hepatic metastasis representing an imminent life-
threatening outcome.
Ibrahim et al. (33) reported the first results of TARE 
in 24 patients with histologically proven ICC, showing 
median OS of 14.9 months from the first treatment. Median 
survival was significantly longer in patients with ECOG 
performance status 0 than in those with status 1 and 2 (31.8 
vs. 6.1 months and 1 month, respectively, P<0.0001) and 
in patients without PVT (31.8 vs. 5.7 months, P=0.0003); 
patients with peripheral ICC had a better survival versus 
those with infiltrative ICC (31.8 months vs. 5.7 months, 
respectively, P=0.0005). A second and more recent study of 
the same group (34) confirmed these initial results; survival 
varied according to the multifocality (5.7 vs. 14.6 months, 
P<0.01), infiltrative vs. peripheral ICC (6.1 vs. 15.6 months, 
P<0.01) or bilobar vs. unilobar disease (10.9 vs. 11.7 months, 
P=0.37).
In a series of 33 patients, Hoffmann et al. (35) reported 
good results, showing a median OS of 22 months from 
the initial TARE treatment: survival was significantly 
improved in patients with ECOG 0, in those with a tumor 
burden ≤25% and in those with tumor response. Saxena 
et al. (36) demonstrated similar results, showing a median 
OS of 9.3 months, significantly correlated to two factors, 
peripheral tumor type (vs. infiltrative, P=0.004) and an 
ECOG performance status (P<0.001). Contrarily, Rafi 
et al. (37) showed a median OS from the first TARE 
of 345±128 days but not correlated with the ECOG 
performance status or extra-hepatic metastases. Al-Adra 
et al. (38) carried out a comprehensive review of the current 
studies and clinical outcomes of unresectable ICCs treated 
with TARE, identifying 12 studies with relevant data. Based 
on a pooled analysis, they found overall weighted median 
survival was 15.5 months. However, the authors pointed 
out the heterogeneity of the study populations included 
in the pooled OS; in fact, all the studies reported survival 
since the initiation of TARE but, in some cases, the patients 
had undergone systemic chemotherapy prior to or during 
the treatment. Therefore, the overall pooled survival may 
underestimate the effects of TARE if some patients had 
already undergone previous therapies.
Recently, Edeline et al. (39) and Mosconi et al. (40) 
showed that TARE combined with chemotherapy seems a 
promising strategy as first-line treatment for unresectable 
intrahepatic cholangiocarcinoma; in particular, Mosconi 
et al. reported a median OS of 17.9 months (95% CI: 
14.3–21.4 months) with better significantly median survival 
in the treatment-naive patients compared with no naive 
patients (52 vs. 16 months, P=0.009). However, it should 
be acknowledged a considerable heterogeneity of data 
reported by the multiple studies in relation to baseline 
clinical features and tumor type and consequently median 
survivals ranging from 9 to 22 months; in fact, to date, 
indications of TARE included patients with peripheral and 
infiltrative type, different tumor burden, as well as patients 
who received previous treatment or not or concomitant 
chemotherapy. Cucchetti et al. (41) recently performed a 
meta-regression study, obtaining two very relevant results: 
first, naïve patients had a 2-year survival of 50.4% vs. 23.6% 
of patients treated with TARE after failure/recurrence of a 
previous treatment, with statistically significant difference; 
second, they reported a median pooled survival of 
19.3 months in patients with peripheral ICC, considerably 
higher than the infiltrative type estimated to be 8.2 months. 
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However, these results are not confirmed by recently paper 
of Gangi et al. which includes 85 patients resulting in the 
most numerous cases published (42); in this paper, median 
OS from radioembolization was 12.0 months and it was 
not significantly longer in treatment-naïve patients or with 
mass-forming type. 
The complications following TARE are not frequent and 
can be further decreased by strict pretreatment assessment 
and carefully selecting patients with preserved liver 
function; post-radioembolization syndrome (PRS), hepatic 
dysfunction, biliary sequelae, portal hypertension, radiation 
pneumonitis, gastrointestinal (GI) ulceration, vascular injury 
and lymphopenia are, even if rare, the most frequently 
adverse events (43). TARE is important therapeutic 
option, with good results about OS and low incidence of 
complications, for patients with unresectable ICC; future 
multicenter randomized trials are necessary to understand 
the role and timing of TARE and other palliative therapies 
in the management of this cancer.
Future directions and conclusions
Despite of the existing evidence that the use of loco-
regional therapies for the management of ICC might 
provide effective local tumor control with limited side-
effects, its utilization on clinical practice is still limited to 
a small number of patients. Amini et al. (44), performed 
an evaluation of 5,388 patients with ICC using the 
Surveillance Epidemiology and End Results. In their 
analysis, authors demonstrated that only 23% of the 
patients with ICC were submitted to local therapies, with 
surgery being the most commonly utilized. Unfortunately, 
only one-third of the patients with ICC are eligible for 
surgical resection at the time of the diagnosis (45). In this 
context, the use of loco-regional oncological therapies 
by interventional radiology might potentially beneficiate 
a significant amount of patients who are ineligible for 
curative resection and further prospective studies should 
be encouraged.
The use of liver ablation, although confined to patients 
with ICC who present with limited disease who are 
otherwise not surgical candidates, has increased nearly six 
fold in the last three decades (44). The wider availability of 
ablation technologies along with its technical refinements 
will likely provide a further increase on the use of ablation 
on patients with ICC. More importantly, validation of 
technical and clinical predictive factors, in particular better 
understanding of tumor molecular biology, will hopefully 
improve patient selection for ablation and its outcomes. 
Similarly, recent improvements on the understanding 
of tumor dose response following TARE (46) will allow 
improving patient selection and refining treatment 
strategies to increase tumor response rates, while 
preserving non-tumorous normal liver parenchyma from 
the deleterious effects of radiation. Finally, the aggressive 
and multicentric nature of ICC requires the need of using 
distinct therapies in a sequential and combined approach 
(Figure 1), highlighting the need of multidisciplinary 
management of such patients for maximum oncological 
control, while preserving liver function and quality of life. 
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